Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan vs irbesartan in hypertensive patients with metabolic syndrome
ChiCTR2300071499Phase 4Recruiting
- Sponsor
- Fuwai Central China Cardiovascular Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of azilsartan in hypertension (HTN) and cardiometabolic risk (CMR) (2 arms), sponsored by Fuwai Central China Cardiovascular Hospital. Primary endpoints: Blood pressure, Fasting blood glucose and 4 more. Started Apr 2023; status: recruiting.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR2300071499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071499.